ClinicalTrials.gg
CompletedNCT04093024InPedILD®Updated Jul 9, 2024Results posted

A Study to Find Out How Nintedanib is Taken up in the Body and How Well it is Tolerated in Children and Adolescents With Interstitial Lung Disease (ILD)

A Phase 3 interventional study of Nintedanib and Placebo in Lung Diseases, Interstitial, sponsored by Boehringer Ingelheim. Completed at 43 sites in 21 countries. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2024-07-09.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
39
Allocation
Randomized
Ages
6 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing nintedanib in Lung Diseases, Interstitial — 1 open to participants now, 1 under way, 1 of them phase 3. nintedanib · Lung Diseases, Interstitial.

Enrollment
9th of 11
39 · median 81
Started
2019
with 1 other
Phase 3
8 of 11
1 open now
Registered
4th of 11
by date
Lead sponsor
6 of 11
Boehringer Ingelheim

Among the 11 studies testing nintedanib in Lung Diseases, Interstitial, this one is the 9th largest by enrollment, is one of 2 that started in 2019, is one of 8 in phase 3, and was the 4th registered.

Lung Diseases, Interstitial

682 studies on the registry are indexed under Lung Diseases, Interstitial; 246 are open to participants now.

Browse Lung Diseases, Interstitial studies →

Open to participants now

1 of the 11 studies testing nintedanib in Lung Diseases, Interstitial is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About nintedanib

nintedanib: first FDA approval 2014 (OFEV), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Lung Diseases, Interstitial studies recruiting now, 108 (62%) set no upper age limit and 25 (14%) stop at 75 or younger; 13 take children under 18; 21 take healthy volunteers.

This study: 6 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing nintedanib in Lung Diseases, Interstitial, or all of them as a file.
02

Study summary

The main objective of the study is to evaluate dose-exposure and safety of nintedanib in children and adolescents with fibrosing Interstitial Lung Disease (ILD).

03

Conditions studied

  • Lung Diseases, Interstitial
04

Who can participate

Ages eligible
6 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children and adolescents 6 to 17 years old at Visit 2.
  • Signed and dated written and assent, where applicable, in accordance with International Conference on Harmonisation-Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial.
  • Male or female patients. Female of (WOCBP) must confirm that sexual abstinence is standard practice and will be continued until 3 months after last drug intake, or be ready and able to use a highly effective method of per International Conference on Harmonisation (ICH) M3 (R2) that results in a low failure rate of less than 1% per year when used consistently and correctly, in combination with one barrier method, from 28 days prior to initiation of study treatment, during treatment and until 3 months after last drug intake. Sexual abstinence is defined as abstinence from any sexual act that may result in pregnancy. A list of contraception methods meeting these criteria is provided in the parental information.
  • Patients with evidence of fibrosing Interstitial Lung Disease (ILD) on High-Resolution Computed Tomography (HRCT) within 12 months of Visit 1 as assessed by the investigator and confirmed by central review.
  • Patients with Forced Vital Capacity (FVC)% predicted ≥25% at Visit 2. [Note: Predicted normal values will be calculated according to GLI (Global Lung Initiative)]
  • Patients with disease at Visit 2, as assessed by the investigator based on any of the following:

    • Fan score ≥3, or
    • Documented evidence of clinical progression over time based on either

      • a 5-10% relative decline in FVC% predicted accompanied by worsening symptoms, or
      • a ≥10% relative decline in FVC % predicted, or
      • increased fibrosis on HRCT, or
      • other measures of clinical worsening attributed to progressive lung disease (e.g. increased oxygen requirement, decreased diffusion capacity).

Exclusion criteria

Exclusion Criteria:

  • (AST) and/or Alanine Aminotransferase (ALT)>1.5 x Upper Level of Normal () at Visit 1.
  • >1.5 x ULN at Visit 1.
  • \<30 mL/min calculated by Schwartz formula at Visit 1. [Note: Laboratory parameters from Visit 1 have to satisfy the laboratory threshold values as shown above. Visit 2 laboratory results will be available only after randomization. In case at Visit 2 the results do no longer satisfy the entry criteria, the Investigator has to decide whether it is justified that the patient remains on study drug. The justification for decision needs to be documented. Laboratory parameters that are found to be abnormal at Visit 1 are allowed to be re-tested (once) if it is thought to be a measurement error (i.e. there was no abnormal result of this test in the recent history of the patient and there is no related clinical sign) or the result of a temporary and reversible medical condition, once that condition is resolved.]
  • Patients with underlying chronic liver disease ( A, B or C hepatic impairment) at Visit 1.
  • Previous treatment with nintedanib.
  • Other therapy received within 1 month or 5 half-lives (whichever is shorter but ≥1 week) prior to Visit 2.
  • Significant pulmonary arterial hypertension (PAH) defined by any of the following:

    • Previous clinical or echocardiographic evidence of significant right heart failure
    • History of right heart catheterization showing a cardiac index ≤2 l/min/m²
    • PAH requiring parenteral therapy with epoprostenol/treprostinil
  • In the opinion of the Investigator, other pulmonary abnormalities.
  • Cardiovascular diseases, any of the following:

    • Severe hypertension, uncontrolled under treatment, within 6 months of Visit 1. Uncontrolled hypertension is defined as

      • In children 6 to ≤12 years old: ≥95th percentile + 12 mm Hg or ≥140/90 mm Hg (whichever is lower) (systolic or diastolic blood pressure equal to or greater than the calculated target value)
      • In adolescents 13 to 17 years old: systolic blood pressure ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg
    • Myocardial infarction within 6 months of Visit 1
    • Unstable cardiac angina within 6 months of Visit 1
  • Bleeding risk, any of the following:

    • Known genetic predisposition to bleeding
    • Patients who require

      • Fibrinolysis, full-dose therapeutic anticoagulation (e.g. vitamin K antagonists, direct thrombin inhibitors, heparin, hirudin)
      • High dose antiplatelet therapy [Note: Prophylactic low dose heparin or heparin flush as needed for maintenance of an indwelling intravenous device (e.g. enoxaparin 4000 I.U. s.c. per day), as well as prophylactic use of antiplatelet therapy (e.g. acetyl salicylic acid up to 325 mg/day, or clopidogrel at 75 mg/day, or equivalent doses of other antiplatelet therapy) are not prohibited.]
    • History of haemorrhagic central nervous system (CNS) event within 12 months of Visit 1
    • Any of the following within 3 months of Visit 1:

      • Haemoptysis or haematuria
      • Active gastro-intestinal (GI) bleeding or GI - ulcers
      • Major injury or surgery (investigator's judgment)
    • Any of the following coagulation parameters at Visit 1:

      • (INR) >2
      • Prolongation of prothrombin time (PT) by >1.5 x ULN
      • Prolongation of activated partial thromboplastin time (aPTT) by >1.5 x ULN
  • History of thrombotic event (including stroke and ) within 12 months of Visit 1.
  • Known to the trial medication or its components (i.e. soya lecithin).
  • Patients with documented allergy to peanut or soya.
  • Other disease that may interfere with testing procedures or in the judgment of the investigator may interfere with trial participation or may put the patient at risk when participating in this trial.
  • for any concomitant disease other than Interstitial Lung Disease (ILD)\<2.5 years (investigator assessment).
  • Female patients who are pregnant, nursing, or who plan to become pregnant while in the trial.
  • Patients not able or willing to adhere to trial procedures, including intake of study medication.
  • Patients with any diagnosed growth disorder such as growth hormone deficiency or any genetic disorder that is associated with short stature (e.g. Turner Syndrome, Noonan Syndrome, Russell-Silver Syndrome) and/or treatment with growth hormone therapy within 6 months before Visit 2. Patients with short stature considered by the investigator to be due to therapy may be included.
  • Patients \<13.5 kg of weight at Visit 1 (same threshold to be used for male and female patients).
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
39 participants (actual)

Study arms

  • Experimental
    Double-blind period (DBP) + open-label Nintedanib period (OLNP): Randomised Nintedanib

    This arm shows Nintedanib randomised participants treated orally with Nintedanib in the DBP and OLNP twice daily with a dose interval of approximately 12 hours from one dose to the next dose. Medication dosage was per administration 50 milligram (mg) \[2 capsules with strength 25 mg\],75 mg \[3 capsules with strength 25 mg\], 100 mg \[1 capsule with strength 100 mg or 4 capsules with strength 25 mg\] or 150 mg \[1 capsule with strength 150 mg or 6 capsules with strength 25 mg\] based on the participant's weight at baseline (= 0 weeks). The dosage was adjusted at subsequent visits if the participant's weight had changed. In this arm participants received Nintedanib in both periods (DBP + OLNP). Participants in this arm do not entail participants from the 'randomised to placebo' arms. DBP: Planned was from first randomised trial drug intake to last blinded drug intake. OLNP: Planned was from first open-label Nintedanib intake to last open-label Nintedanib intake.

    Drug: Nintedanib

  • Placebo comparator
    DBP+OLNP: Randomised placebo

    Placebo randomised participants were treated orally with a Nintedanib matching placebo soft capsule twice daily in the double-blind period (DBP). Participants who continued with the open-label Nintedanib period (OLNP) after the DBP switched to active Nintedanib treatment in the OLNP and were treated orally with Nintedanib twice daily. Medication dosage was per administration 50 milligram (mg) \[2 25 mg capsules (cap)\],75 mg \[3 25 mg cap\], 100 mg \[1 100 mg or 4 25 mg cap\] or 150 mg \[1 150 mg or 6 25 mg cap\] based on the participant's weight at baseline (= 0 weeks). The dosage was adjusted at subsequent visits if the participant's weight had changed. The dose interval was approximately 12 hours between one and the next dose. Here participants received placebo first (DBP) and then Nintedanib (OLNP). DBP: Planned was from first to last randomised blinded drug intake. OLNP: Planned was from first to last open-label Nintedanib intake.

    Drug: Placebo

Interventions

  • Capsule

    Also known as: Ofev®

  • DrugPlacebo

    Capsule

06

What researchers measure

Primary outcomes

  1. Area Under the Plasma Concentration-time Curve at Steady State (AUCτ,ss) Based on Sampling at Steady State (at Week 2 and Week 26)

    Area under the plasma concentration-time curve at steady state (AUCt,ss) based on sampling at steady state (at Week 2 and Week 26) after multiple oral administration of Nintedanib by age group over all treatments. Values of samples taken at Week 2 (for randomised Nintedanib participants) and at Week 26 (for randomised placebo participants) were used. Missing values at Week 2 of randomised Nintedanib participants were replaced with values taken at Week 26.

    Time frame: At Week 2 and at Week 26: at 5 minutes before and at 0, 1, 2, 3, 4, 6, and 8 hours post administration of the morning dose

  2. Number of Participants With Treatment-emergent Adverse Events During the Double-blind Period

    Treatment-emergent was defined as: Adverse events with onset or worsening on or after date of treatment start until end of double-blind period (defined as the day before first intake of open-label nintedanib or last double-blind drug intake + residual effect period, whichever is earlier) were considered as treatment-emergent and were included in the analysis. Adverse events were counted under the treatment as randomized for the double-blind period.

    Time frame: From first drug administration until the earlier of (i) first intake of open-label nintedanib (exclusive) and (ii) last drug intake, up to 28 weeks

Secondary outcomes

  1. Number of Participants With at Least One Treatment-emergent Pathological Finding of Epiphyseal Growth Plate on Imaging up to Week 24, and Week 52

    Number of participants with at least one treatment-emergent pathological finding of the epiphyseal growth plate imaging (Magnetic Resonance Imaging (MRI)s/x-rays) were analyzed cumulatively and based on central review.

    Time frame: Up to Week 24 (included values at Week 12 and Week 24); Up to Week 52 (included values at Week 12, 24, 36 and 52)

  2. Number of Participants With Treatment-emergent Pathological Findings on Dental Examination or Imaging up to Week 24

    Number of participants with treatment-emergent pathological findings on dental examination (clinical examination) based on dentist assessment or imaging (panoramic x-ray) based on central review were analyzed. Number of participants with treatment-emergent pathological findings on dental imaging were analyzed cumulatively.

    Time frame: Dental examination: at Week 12 and Week 24; Dental imaging: at Week 24

  3. Number of Participants With at Least One Treatment-emergent Pathological Findings on Dental Examination or Imaging up to Week 52

    Number of participants with treatment-emergent pathological findings on dental examination (clinical examination) based on dentist assessment or imaging (panoramic x-ray) based on central review were analyzed. Number of participants with treatment-emergent pathological findings on dental imaging were analyzed cumulatively.

    Time frame: Dental examination: at Week 12, 24, 34, and Week 52; Dental imaging: at Week 24 and at Week 52.

  4. Number of Participants With Treatment-emergent Adverse Events Over the Whole Trial

    Treatment-emergent was defined as: Adverse events with onset or worsening on or after date of treatment start until last drug intake + residual effect period was considered as treatment-emergent and was included in the analysis. Adverse events were counted under the treatment as randomized for the double-blind period.

    Time frame: From first drug administration until the last drug intake, up to 92 weeks

  5. Absolute Change From Baseline in Height at Week 24

    Absolute change from baseline in height at Week 24 was measured with a stadiometer 3 times at each time point. The average of these 3 measurements was taken per time point. Absolute change from baseline in height at Week 24 in the treated set (TS) was based on a Mixed Model Repeated Measures (MMRM), with fixed categorical effects of (randomised) treatment at each visit, age-group and the fixed continuous effects of baseline at each visit, and random effect for participant. Visit was treated as the repeated measure with an unstructured covariance structure used to model the within-participant measurements.

    Time frame: MMRM included measurements pre-administration at -4 weeks and at 0, 12, 24, 36, 52, 64, 76, and 88 weeks after first drug administration. MMRM values at Week 24 are reported in the table below

  6. Absolute Change From Baseline in Height at Week 52

    Absolute change from baseline in height at Week 52 was measured with a stadiometer 3 times at each time point. The average of these 3 measurements was taken per time point. Absolute change from baseline in height at Week 52 in the treated set (TS) was based on a Mixed Model Repeated Measures (MMRM), with fixed categorical effects of (randomised) treatment at each visit, age-group and the fixed continuous effects of baseline at each visit, and random effect for participant. Visit was treated as the repeated measure with an unstructured covariance structure used to model the within-participant measurements.

    Time frame: MMRM included measurements pre-administration at -4 weeks and at 0, 12, 24, 36, 52, 64, 76, and 88 weeks after first drug administration. MMRM values at Week 52 are reported in the table below

  7. Absolute Change From Baseline in Height at Week 76

    Absolute change from baseline in height at Week 76 was measured with a stadiometer 3 times at each time point. The average of these 3 measurements was taken per time point. MMRM has been calculated but did not provide estimates for this time point due to low sample size. Thus, change in height from baseline to Week 76 was analyzed descriptively only.

    Time frame: Measurements were assessed at Week 0 and at Week 76

  8. Absolute Change From Baseline in Sitting Height at Week 24

    Absolute change from baseline in sitting height at Week 24 was measured with a stadiometer 3 times at each time point. The average of these 3 measurements was taken per time point. Absolute change from baseline in sitting height at Week 24 in the treated set (TS) was based on a Mixed Model Repeated Measures (MMRM), with fixed categorical effects of (randomised) treatment at each visit, age-group and the fixed continuous effects of baseline at each visit, and random effect for participant. Visit was treated as the repeated measure with an unstructured covariance structure used to model the within-participant measurements.

    Time frame: MMRM included measurements pre-administration at -4 weeks and at 0, 12, 24, 36, 52, 64, 76, and 88 weeks after first drug administration. MMRM values at Week 24 are reported in the table below.

  9. Absolute Change From Baseline in Sitting Height at Week 52

    Absolute change from baseline in sitting height at Week 52 was measured with a stadiometer 3 times at each time point. The average of these 3 measurements was taken per time point. MMRM has been calculated but did not provide estimates for this time point due to low sample size. Thus, change in sitting height from baseline to Week 52 was analyzed descriptively only.

    Time frame: Measurements were assessed at Week 0 and at Week 52

  10. Absolute Change From Baseline in Sitting Height at Week 76

    Absolute change from baseline in sitting height at Week 76 was measured with a stadiometer 3 times at each time point. The average of these 3 measurements was take per time point. MMRM has been calculated but did not provide estimates for this time point due to low sample size. Thus, change in sitting height from baseline to Week 76 was analyzed descriptively only.

    Time frame: Measurements were assessed at Week 0 and at Week 76

  11. Absolute Change From Baseline in Leg Length at Week 24 - Left

    Absolute change from baseline in left leg length at Week 24 was assessed by measuring the distance between the anterior iliac spine and the medial malleolus 3 times at each leg and each time point. The average of these 3 measurements was taken per time point. Absolute change from baseline in left leg length at Week 24 in the treated set (TS) was based on a Mixed Model Repeated Measures (MMRM), with fixed categorical effects of (randomised) treatment at each visit, age-group and the fixed continuous effects of baseline at each visit, and random effect for participant. Visit was treated as the repeated measure with an unstructured covariance structure used to model the within-participant measurements.

    Time frame: MMRM included measurements at 0, 12, 24, 36, 52, 64, and 76 weeks after first drug administration. MMRM values at Week 24 are reported in the table below

  12. Absolute Change From Baseline in Leg Length at Week 52 - Left

    Absolute change from baseline in left leg length at Week 52 was assessed by measuring the distance between the anterior iliac spine and the medial malleolus 3 times at each leg and each time point. The average of these 3 measurements was taken per time point. Absolute change from baseline in left leg length at Week 52 in the treated set (TS) was based on a Mixed Model Repeated Measures (MMRM), with fixed categorical effects of (randomised) treatment at each visit, age-group and the fixed continuous effects of baseline at each visit, and random effect for participant. Visit was treated as the repeated measure with an unstructured covariance structure used to model the within-participant measurements.

    Time frame: MMRM included measurements at 0, 12, 24, 36, 52, 64, and 76 weeks after first drug administration. MMRM values at Week 52 are reported in the table below

  13. Absolute Change From Baseline in Leg Length at Week 76 - Left

    Absolute change from baseline in left leg length at Week 76 was assessed by measuring the distance between the anterior iliac spine and the medial malleolus 3 times at each leg and each time point. The average of these 3 measurements was taken per time point. Absolute change from baseline in left leg length at Week 76 in the treated set (TS) was based on a Mixed Model Repeated Measures (MMRM), with fixed categorical effects of (randomised) treatment at each visit, age-group and the fixed continuous effects of baseline at each visit, and random effect for participant. Visit was treated as the repeated measure with an unstructured covariance structure used to model the within-participant measurements.

    Time frame: MMRM included measurements at 0, 12, 24, 36, 52, 64, and 76 weeks after first drug administration. MMRM values at Week 76 are reported in the table below

  14. Absolute Change From Baseline in Leg Length at Week 24 - Right

    Absolute change from baseline in right leg length at Week 24 was assessed by measuring the distance between the anterior iliac spine and the medial malleolus 3 times at each leg and each time point. The average of these 3 measurements was taken per time point. Absolute change from baseline in right leg length at Week 24 in the treated set (TS) was based on a Mixed Model Repeated Measures (MMRM), with fixed categorical effects of (randomised) treatment at each visit, age-group and the fixed continuous effects of baseline at each visit, and random effect for participant. Visit was treated as the repeated measure with an unstructured covariance structure used to model the within-participant measurements.

    Time frame: MMRM included measurements at 0, 12, 24, 36, 52, 64, and 76 weeks after first drug administration. MMRM values at Week 24 are reported in the table below

  15. Absolute Change From Baseline in Leg Length at Week 52 - Right

    Absolute change from baseline in right leg length at Week 52 was assessed by measuring the distance between the anterior iliac spine and the medial malleolus 3 times at each leg and each time point. The average of these 3 measurements was taken per time point. Absolute change from baseline in right leg length at Week 52 in the treated set (TS) was based on a Mixed Model Repeated Measures (MMRM), with fixed categorical effects of (randomised) treatment at each visit, age-group and the fixed continuous effects of baseline at each visit, and random effect for participant. Visit was treated as the repeated measure with an unstructured covariance structure used to model the within-participant measurements.

    Time frame: MMRM included measurements at 0, 12, 24, 36, 52, 64, and 76 weeks after first drug administration. MMRM values at Week 52 are reported in the table below

  16. Absolute Change From Baseline in Leg Length at Week 76 - Right

    Absolute change from baseline in right leg length at Week 76 was assessed by measuring the distance between the anterior iliac spine and the medial malleolus 3 times at each leg and each time point. The average of these 3 measurements was taken per time point. Absolute change from baseline in right leg length at Week 76 in the treated set (TS) was based on a Mixed Model Repeated Measures (MMRM), with fixed categorical effects of (randomised) treatment at each visit, age-group and the fixed continuous effects of baseline at each visit, and random effect for participant. Visit was treated as the repeated measure with an unstructured covariance structure used to model the within-participant measurements.

    Time frame: MMRM included measurements at 0, 12, 24, 36, 52, 64, and 76 weeks after first drug administration. MMRM values at Week 76 are reported in the table below

  17. Absolute Change From Baseline in Forced Vital Capacity (FVC) % Predicted at Week 24

    Forced Vital Capacity (FVC) is the volume of air (measured in milliliter) which can be forcibly exhaled from the lungs after taking the deepest breath possible. The predicted values were calculated according to the Global Lungs Initiative (GLI) 2012 equations. Absolute change from baseline in Forced Vital Capacity (FVC) % predicted at Week 24 in the treated set(TS) was based on a Mixed Model Repeated Measures (MMRM), with fixed categorical effects of (randomised) treatment at each visit, age-group and the fixed continuous effects of baseline at each visit, and random effect for participant. Visit was treated as the repeated measure with an unstructured covariance structure used to model the within-participant measurements.

    Time frame: MMRM included measurements pre-administration at -4 weeks and at 0, 2, 6, 12, 24, 26, 36, and 52 weeks after first drug administration. MMRM values at Week 24 are reported in the table below

  18. Absolute Change From Baseline in Forced Vital Capacity (FVC) % Predicted at Week 52

    Forced Vital Capacity (FVC) is the volume of air (measured in milliliter) which can be forcibly exhaled from the lungs after taking the deepest breath possible. The predicted values were calculated according to the Global Lungs Initiative (GLI) 2012 equations. Absolute change from baseline in Forced Vital Capacity (FVC) % predicted at Week 52 in the treated set(TS) was based on a Mixed Model Repeated Measures (MMRM), with fixed categorical effects of (randomised) treatment at each visit, age-group and the fixed continuous effects of baseline at each visit, and random effect for participant. Visit was treated as the repeated measure with an unstructured covariance structure used to model the within-participant measurements.

    Time frame: MMRM included measurements pre-administration at -4 weeks and at 0, 2, 6, 12, 24, 26, 36, and 52 weeks after first drug administration. MMRM values at Week 52 are reported in the table below

  19. Absolute Change From Baseline in Pediatric Quality of Life Questionnaire™(PedsQL™) at Week 24 - Parent Report

    The PedsQL™ questionnaires consists of 23 items (i) and 4 dimensions: physical (8i), emotional (5i), social (5i) and school (5i) functioning. A 5-point Likert response scale (0 = never (worst outcome) to 4=almost always (best outcome)) was used except for the Young Child Report, where a 3-point scale (0=not at all (worst outcome) to 4=a lot (best outcome)) was used. Items were reverse-scored and linearly transformed to a 0-100 scale (0 = 100 to 4 = 0). Higher scores indicated better health-related quality of life. To create total scores, the mean was computed. Absolute change from baseline in PedsQL™ reported by parents was based on a Mixed Model Repeated Measures (MMRM), with fixed categorical effects of (randomised) treatment at each visit, age-group and the fixed continuous effects of baseline at each visit, and random effect for participant. Visit was treated as the repeated measure with an unstructured covariance structure used to model the within-participant measurements.

    Time frame: MMRM included measurements at 0, 24, and 52 weeks after first drug administration. MMRM values at Week 24 are reported in the table below

  20. Absolute Change From Baseline in Pediatric Quality of Life Questionnaire™(PedsQL™) at Week 52 - Parent Report

    The PedsQL™ questionnaires consists of 23 items (i) and 4 dimensions: physical (8i), emotional (5i), social (5i) and school (5i) functioning. A 5-point Likert response scale (0 = never (worst outcome) to 4=almost always (best outcome)) was used except for the Young Child Report, where a 3-point scale (0=not at all (worst outcome) to 4=a lot (best outcome)) was used. Items were reverse-scored and linearly transformed to a 0-100 scale (0 = 100 to 4 = 0). Higher scores indicated better health-related quality of life. To create total scores, the mean was computed. Absolute change from baseline in PedsQL™ reported by parents was based on a Mixed Model Repeated Measures (MMRM), with fixed categorical effects of (randomised) treatment at each visit, age-group and the fixed continuous effects of baseline at each visit, and random effect for participant. Visit was treated as the repeated measure with an unstructured covariance structure used to model the within-participant measurements.

    Time frame: MMRM included measurements at 0, 24, and 52 weeks after first drug administration. MMRM values at Week 52 are reported in the table below

  21. Absolute Change From Baseline in Pediatric Quality of Life Questionnaire™(PedsQL™) at Week 24 - Participant Report

    The PedsQL™ questionnaires consists of 23 items (i) and 4 dimensions: physical (8i), emotional (5i), social (5i) and school (5i) functioning. A 5-point Likert response scale (0 = never (worst outcome) to 4=almost always (best outcome)) was used except for the Young Child Report, where a 3-point scale (0=not at all (worst outcome) to 4=a lot (best outcome)) was used. Items were reverse-scored and linearly transformed to a 0-100 scale (0 = 100 to 4 = 0). Higher scores indicated better health-related quality of life. To create total scores, the mean was computed. Absolute change from baseline in PedsQL™ was based on a Mixed Model Repeated Measures (MMRM), with fixed categorical effects of (randomised) treatment at each visit, age-group and the fixed continuous effects of baseline at each visit, and random effect for participant. Visit was treated as the repeated measure with an unstructured covariance structure used to model the within-participant measurements.

    Time frame: MMRM included measurements at 0, 24, and 52 weeks after first drug administration. MMRM values at Week 24 are reported in the table below

  22. Absolute Change From Baseline in Pediatric Quality of Life Questionnaire™(PedsQL™) at Week 52 - Participant Report

    The PedsQL™ questionnaires consists of 23 items (i) and 4 dimensions: physical (8i), emotional (5i), social (5i) and school (5i) functioning. A 5-point Likert response scale (0 = never (worst outcome) to 4=almost always (best outcome)) was used except for the Young Child Report, where a 3-point scale (0=not at all (worst outcome) to 4=a lot (best outcome)) was used. Items were reverse-scored and linearly transformed to a 0-100 scale (0 = 100 to 4 = 0). Higher scores indicated better health-related quality of life. To create total scores, the mean was computed. Absolute change from baseline in PedsQL™ was based on a Mixed Model Repeated Measures (MMRM), with fixed categorical effects of (randomised) treatment at each visit, age-group and the fixed continuous effects of baseline at each visit, and random effect for participant. Visit was treated as the repeated measure with an unstructured covariance structure used to model the within-participant measurements.

    Time frame: MMRM included measurements at 0, 24, and 52 weeks after first drug administration. MMRM values at Week 52 are reported in the table below

  23. Absolute Change From Baseline in Oxygen Saturation (SpO₂) on Room Air at Rest at Week 24

    Oxygen saturation (SpO₂) was measured after minimum 5 minutes on room air by standard pulse oximetry at rest. Absolute change from baseline in SpO₂ at Week 24 in the treated set(TS) was based on a Mixed Model Repeated Measures (MMRM), with fixed categorical effects of (randomised) treatment at each visit, age-group and the fixed continuous effects of baseline at each visit, and random effect for participant. Visit was treated as the repeated measure with an unstructured covariance structure used to model the within-participant measurements.

    Time frame: MMRM included measurements pre-administration at -4 weeks and at 0, 2, 6, 12, 24, 26, 36, and 52 weeks after first drug administration. MMRM values at Week 24 are reported in the table below

  24. Absolute Change From Baseline in Oxygen Saturation (SpO₂) on Room Air at Rest at Week 52

    Oxygen saturation (SpO₂) was measured after minimum 5 minutes on room air by standard pulse oximetry at rest. Absolute change from baseline in SpO₂ at Week 52 in the treated set(TS) was based on a Mixed Model Repeated Measures (MMRM), with fixed categorical effects of (randomised) treatment at each visit, age-group and the fixed continuous effects of baseline at each visit, and random effect for participant. Visit was treated as the repeated measure with an unstructured covariance structure used to model the within-participant measurements.

    Time frame: MMRM included measurements pre-administration at -4 weeks and at 0, 2, 6, 12, 24, 26, 36, and 52 weeks after first drug administration. MMRM values at Week 52 are reported in the table below

  25. Absolute Change From Baseline in 6 Minutes (Min) Walk Distance at Week 24

    Absolute change from baseline in 6 minutes (min) walk distance at Week 24 in the treated set (TS) was based on a Mixed Model Repeated Measures (MMRM), with fixed categorical effects of (randomised) treatment at each visit, age-group and the fixed continuous effects of baseline at each visit, and random effect for participant. Visit was treated as the repeated measure with an unstructured covariance structure used to model the within-participant measurements.

    Time frame: MMRM included measurements at 0, 24, and 52 weeks after first drug administration. MMRM values at Week 24 are reported in the table below

  26. Absolute Change From Baseline in 6 Minutes (Min) Walk Distance at Week 52

    Absolute change from baseline in 6 minutes (min) walk distance at Week 52 in the treated set(TS) was based on a Mixed Model Repeated Measures (MMRM), with fixed categorical effects of (randomised) treatment at each visit, age-group and the fixed continuous effects of baseline at each visit, and random effect for participant. Visit was treated as the repeated measure with an unstructured covariance structure used to model the within-participant measurements.

    Time frame: MMRM included measurements at 0, 24, and 52 weeks after first drug administration. MMRM values at Week 52 are reported in the table below

  27. Participants Acceptability Based on the Size of Capsules at Week 24 - Patient Question

    Acceptability is defined as the overall ability and willingness of the participant to use the medicinal product as intended. Acceptability based on the capsule size was assessed by a acceptability questionnaire (1 item with 3 categories as shown below) for participants. In case the participant was considered not old enough as per investigator judgment the caregiver could assist with the completion. In addition to the commercially available 100 milligram (mg) soft capsules (oblong shape, 6 millimeter (mm) diameter and 16 mm length) and 150 mg soft capsules (oblong shape, 7 mm diameter and 18 mm length), 25 mg Nintedanib soft capsules of smaller size (oval shape, 5 mm diameter and 8 mm length) were provided in this trial for participants who were assigned to a dose smaller than 100 mg or were unable to swallow the larger 100 mg or 150 mg capsules.

    Time frame: Acceptability was assessed at Week 24

  28. Participants Acceptability Based on the Size of Capsules at Week 24 - Investigator Question

    Acceptability is defined as the overall ability and willingness of the participant to use the medicinal product as intended. Acceptability based on the capsule size was assessed by a acceptability questionnaire (1 item with 3 categories as shown below) for investigators. In addition to the commercially available 100 milligram (mg) soft capsules (oblong shape, 6 millimeter (mm) diameter and 16 mm length) and 150 mg soft capsules (oblong shape, 7 mm diameter and 18 mm length), 25 mg Nintedanib soft capsules of smaller size (oval shape, 5 mm diameter and 8 mm length) were provided in this trial for participants who were assigned to a dose smaller than 100 mg or were unable to swallow the larger 100 mg or 150 mg capsules.

    Time frame: Acceptability was assessed at Week 24

  29. Participants Acceptability Based on the Number of Capsules at Week 24 - Patient Question

    Acceptability is defined as the overall ability and willingness of the participant to use the medicinal product as intended. Acceptability based on the number of capsule was assessed by a acceptability questionnaire (1 item with 3 categories as shown below) for participants. In case the participant was considered not old enough as per investigator judgment the caregiver could assist with the completion. In addition to the commercially available 100 milligram (mg) soft capsules (oblong shape, 6 millimeter (mm) diameter and 16 mm length) and 150 mg soft capsules (oblong shape, 7 mm diameter and 18 mm length), 25 mg Nintedanib soft capsules of smaller size (oval shape, 5 mm diameter and 8 mm length) were provided in this trial for participants who were assigned to a dose smaller than 100 mg or were unable to swallow the larger 100 mg or 150 mg capsules. Medication dosage was based on the participant's body weight and number of capsules per administration ranged from 2 to \>6 capsules.

    Time frame: Acceptability was assessed at Week 24

  30. Number of Participants With Occurrence of First Respiratory-related Hospitalization Over the Whole Trial

    Number of participants with occurrence of first respiratory-related hospitalization over the whole trial. The number of participants with first respiratory-related hospitalization is reported instead of a metric summarizing the time-to-event data with unit of time, as the numbers resulting from the Kaplan-Meier-analysis were even below the first quartile.

    Time frame: From first drug administration until the last drug intake + 28 days residual effect period (REP), up to 92.6 weeks

  31. Number of Participants With Occurrence of First Acute Interstitial Lung Disease (ILD) Exacerbation or Death Over the Whole Trial

    Number of participants with occurrence of first acute Interstitial Lung Disease (ILD) exacerbation or death over the whole trial. The number of participants with first acute ILD exacerbation is reported instead of a metric summarizing the time-to-event data with unit of time, as the numbers resulting from the Kaplan-Meier-analysis were even below the first quartile.

    Time frame: From first drug administration until the last drug intake + 28 days REP, up to 92.6 weeks

  32. Number of Participants With Occurrence of Death Over the Whole Trial

    Number of participants with occurrence of death over the whole trial over the whole trial was computed. The number of participants with occurrence of death is reported instead of a metric summarizing the time-to-event data with unit of time, as the numbers resulting from the Kaplan-Meier-analysis were even below the first quartile.

    Time frame: From first drug administration until the last drug intake + 28 days REP, up to 92.6 weeks

07

Results

Posted Jan 31, 2023
Limitations and caveats
In the protocol it was planned to communicate the end of trial (EoT) once 30 participants had completed pharmacokinetic (PK) sampling at Week 26 or prematurely discontinued the trial and PK data was confirmed as adequate. When the EoT was communicated, no participant had reached Week 100 yet, thus Week 100 time points were not assessable and the trial was completed as per protocol.

Participant flow

This was a multicenter, multinational, prospective clinical trial to evaluate the dose-exposure and safety of Nintedanib on top of standard of care (SOC) in children and adolescents (6 to 17 years old) with clinically significant fibrosing Interstitial Lung Disease (ILD) in two parts. A randomised, placebo-controlled, double-blind treatment period of 24 weeks (double-blind period (DBP)) was followed by an open-label Nintedanib period (OLNP)) of variable duration.

Double-blind Period
Participant flow — Double-blind Period
MilestoneDBP+OLNP: Randomised to PlaceboDBP+OLNP: Randomised to Nintedanib
Started1326
Completed1121
Not completed25
Withdrew: Completed prematurely due to administrative end of trial and did not continue with olnp22
Withdrew: Discontinued treatment due to adverse event02
Withdrew: Discontinued treatment due to other reason01
Open-label Nintedanib Period (OLNP)
Participant flow — Open-label Nintedanib Period (OLNP)
MilestoneDBP+OLNP: Randomised to PlaceboDBP+OLNP: Randomised to Nintedanib
Started1121
Completed1120
Not completed01
Withdrew: Discontinuation of trial medication due to other reason01

Outcome measures

PrimaryArea Under the Plasma Concentration-time Curve at Steady State (AUCτ,ss) Based on Sampling at Steady State (at Week 2 and Week 26)

Area under the plasma concentration-time curve at steady state (AUCt,ss) based on sampling at steady state (at Week 2 and Week 26) after multiple oral administration of Nintedanib by age group over all treatments. Values of samples taken at Week 2 (for randomised Nintedanib participants) and at Week 26 (for randomised placebo participants) were used. Missing values at Week 2 of randomised Nintedanib participants were replaced with values taken at Week 26.

Time frame:
At Week 2 and at Week 26: at 5 minutes before and at 0, 1, 2, 3, 4, 6, and 8 hours post administration of the morning dose
Reported as:
Geometric mean · Hours times nanogram per mililiter
Area Under the Plasma Concentration-time Curve at Steady State (AUCτ,ss) Based on Sampling at Steady State (at Week 2 and Week 26)
Hours times nanogram per mililiterDBP+OLNP: 6 to < 12 Years - Exposed to NintedanibDBP+OLNP: 12 to <18 Years - Exposed to Nintedanib
Area Under the Plasma Concentration-time Curve at Steady State (AUCτ,ss) Based on Sampling at Steady State (at Week 2 and Week 26)175 ± 85.1167 ± 83.6
PrimaryNumber of Participants With Treatment-emergent Adverse Events During the Double-blind Period

Treatment-emergent was defined as: Adverse events with onset or worsening on or after date of treatment start until end of double-blind period (defined as the day before first intake of open-label nintedanib or last double-blind drug intake + residual effect period, whichever is earlier) were considered as treatment-emergent and were included in the analysis. Adverse events were counted under the treatment as randomized for the double-blind period.

Time frame:
From first drug administration until the earlier of (i) first intake of open-label nintedanib (exclusive) and (ii) last drug intake, up to 28 weeks
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events During the Double-blind Period
ParticipantsDBP: Randomised to PlaceboDBP: Randomised to Nintedanib
Number of Participants With Treatment-emergent Adverse Events During the Double-blind Period1122
SecondaryNumber of Participants With at Least One Treatment-emergent Pathological Finding of Epiphyseal Growth Plate on Imaging up to Week 24, and Week 52

Number of participants with at least one treatment-emergent pathological finding of the epiphyseal growth plate imaging (Magnetic Resonance Imaging (MRI)s/x-rays) were analyzed cumulatively and based on central review.

Time frame:
Up to Week 24 (included values at Week 12 and Week 24); Up to Week 52 (included values at Week 12, 24, 36 and 52)
Reported as:
Count of participants · Participants
Number of Participants With at Least One Treatment-emergent Pathological Finding of Epiphyseal Growth Plate on Imaging up to Week 24, and Week 52
ParticipantsDBP+OLNP: Randomised to PlaceboDBP+OLNP: Randomised to Nintedanib
At Week 2412
At Week 5223
SecondaryNumber of Participants With Treatment-emergent Pathological Findings on Dental Examination or Imaging up to Week 24

Number of participants with treatment-emergent pathological findings on dental examination (clinical examination) based on dentist assessment or imaging (panoramic x-ray) based on central review were analyzed. Number of participants with treatment-emergent pathological findings on dental imaging were analyzed cumulatively.

Time frame:
Dental examination: at Week 12 and Week 24; Dental imaging: at Week 24
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Pathological Findings on Dental Examination or Imaging up to Week 24
ParticipantsDBP: Randomised to PlaceboDBP: Randomised to Nintedanib
Dental examination: Pathological findings up to week 2415
Dental imaging: Stunted growth of dental root06
Dental imaging: Accelerated growth of dental root00
Dental imaging: extra / supernumerary teeth00
Dental imaging: Impacted permanent teeth24
Dental imaging: Additional findings15
Dental imaging: Other findings21
SecondaryNumber of Participants With at Least One Treatment-emergent Pathological Findings on Dental Examination or Imaging up to Week 52

Number of participants with treatment-emergent pathological findings on dental examination (clinical examination) based on dentist assessment or imaging (panoramic x-ray) based on central review were analyzed. Number of participants with treatment-emergent pathological findings on dental imaging were analyzed cumulatively.

Time frame:
Dental examination: at Week 12, 24, 34, and Week 52; Dental imaging: at Week 24 and at Week 52.
Reported as:
Count of participants · Participants
Number of Participants With at Least One Treatment-emergent Pathological Findings on Dental Examination or Imaging up to Week 52
ParticipantsDBP+OLNP: Randomised to PlaceboDBP+OLNP: Randomised to Nintedanib
Dental examination: Pathological findings up to week 5237
Dental imaging: Stunted growth of dental root06
Dental imaging: Accelerated growth of dental root00
Dental imaging: extra / supernumerary teeth00
Dental imaging: Impacted permanent teeth25
Dental imaging: Additional findings16
Dental imaging: Other findings32
SecondaryNumber of Participants With Treatment-emergent Adverse Events Over the Whole Trial

Treatment-emergent was defined as: Adverse events with onset or worsening on or after date of treatment start until last drug intake + residual effect period was considered as treatment-emergent and was included in the analysis. Adverse events were counted under the treatment as randomized for the double-blind period.

Time frame:
From first drug administration until the last drug intake, up to 92 weeks
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events Over the Whole Trial
ParticipantsDBP: Randomised to PlaceboOLNP: Randomised to Placebo and Switched to NintedanibDBP+OLNP: Randomised to Nintedanib
Number of Participants With Treatment-emergent Adverse Events Over the Whole Trial111126
SecondaryAbsolute Change From Baseline in Height at Week 24

Absolute change from baseline in height at Week 24 was measured with a stadiometer 3 times at each time point. The average of these 3 measurements was taken per time point. Absolute change from baseline in height at Week 24 in the treated set (TS) was based on a Mixed Model Repeated Measures (MMRM), with fixed categorical effects of (randomised) treatment at each visit, age-group and the fixed continuous effects of baseline at each visit, and random effect for participant. Visit was treated as the repeated measure with an unstructured covariance structure used to model the within-participant measurements.

Time frame:
MMRM included measurements pre-administration at -4 weeks and at 0, 12, 24, 36, 52, 64, 76, and 88 weeks after first drug administration. MMRM values at Week 24 are reported in the table below
Reported as:
Least squares mean · Centimeter
Absolute Change From Baseline in Height at Week 24
CentimeterDBP: Randomised to PlaceboDBP: Randomised to Nintedanib
Absolute Change From Baseline in Height at Week 241.3 (0.6 to 1.9)1.3 (0.8 to 1.8)
Statistical analysis
  • DBP: Randomised to Placebo vs DBP: Randomised to Nintedanib · Mixed Model Repeated Measures (MMRM) · p = 0.9858 · Adjusted mean difference: 0.0 · 95% CI -0.8 to 0.8Adjusted mean difference was calculated as 'Randomised Nintedanib - randomised placebo'.
SecondaryAbsolute Change From Baseline in Height at Week 52

Absolute change from baseline in height at Week 52 was measured with a stadiometer 3 times at each time point. The average of these 3 measurements was taken per time point. Absolute change from baseline in height at Week 52 in the treated set (TS) was based on a Mixed Model Repeated Measures (MMRM), with fixed categorical effects of (randomised) treatment at each visit, age-group and the fixed continuous effects of baseline at each visit, and random effect for participant. Visit was treated as the repeated measure with an unstructured covariance structure used to model the within-participant measurements.

Time frame:
MMRM included measurements pre-administration at -4 weeks and at 0, 12, 24, 36, 52, 64, 76, and 88 weeks after first drug administration. MMRM values at Week 52 are reported in the table below
Reported as:
Least squares mean · Centimeter
Absolute Change From Baseline in Height at Week 52
CentimeterDBP+OLNP: Randomised to PlaceboDBP+OLNP: Randomised to Nintedanib
Absolute Change From Baseline in Height at Week 522.8 (1.5 to 4.2)2.8 (1.8 to 3.8)
Statistical analysis
  • DBP+OLNP: Randomised to Placebo vs DBP+OLNP: Randomised to Nintedanib · Mixed Model Repeated Measures (MMRM) · p = 0.9769 · Adjusted mean difference: -0.0 · 95% CI -1.7 to 1.6Adjusted mean difference was calculated as 'Randomised Nintedanib - randomised placebo'.
SecondaryAbsolute Change From Baseline in Height at Week 76

Absolute change from baseline in height at Week 76 was measured with a stadiometer 3 times at each time point. The average of these 3 measurements was taken per time point. MMRM has been calculated but did not provide estimates for this time point due to low sample size. Thus, change in height from baseline to Week 76 was analyzed descriptively only.

Time frame:
Measurements were assessed at Week 0 and at Week 76
Reported as:
Mean · Centimeter
Absolute Change From Baseline in Height at Week 76
CentimeterDBP+OLNP: Randomised to PlaceboDBP+OLNP: Randomised to Nintedanib
At Baseline143.7 ± 11.2162.5 ± 15.8
At Week 76150.0 ± 15.7165.5 ± 13.0
SecondaryAbsolute Change From Baseline in Sitting Height at Week 24

Absolute change from baseline in sitting height at Week 24 was measured with a stadiometer 3 times at each time point. The average of these 3 measurements was taken per time point. Absolute change from baseline in sitting height at Week 24 in the treated set (TS) was based on a Mixed Model Repeated Measures (MMRM), with fixed categorical effects of (randomised) treatment at each visit, age-group and the fixed continuous effects of baseline at each visit, and random effect for participant. Visit was treated as the repeated measure with an unstructured covariance structure used to model the within-participant measurements.

Time frame:
MMRM included measurements pre-administration at -4 weeks and at 0, 12, 24, 36, 52, 64, 76, and 88 weeks after first drug administration. MMRM values at Week 24 are reported in the table below.
Reported as:
Least squares mean · Centimeters
Absolute Change From Baseline in Sitting Height at Week 24
CentimetersDBP: Randomised to PlaceboDBP: Randomised to Nintedanib
Absolute Change From Baseline in Sitting Height at Week 241.0 (-1.3 to 3.4)2.1 (0.6 to 3.6)
Statistical analysis
  • DBP: Randomised to Placebo vs DBP: Randomised to Nintedanib · Mixed Model Repeated Measures (MMRM) · p = 0.4442 · Adjusted mean difference: 1.1 · 95% CI -1.8 to 4.0Adjusted mean difference was calculated as 'Randomised Nintedanib - randomised placebo'.
SecondaryAbsolute Change From Baseline in Sitting Height at Week 52

Absolute change from baseline in sitting height at Week 52 was measured with a stadiometer 3 times at each time point. The average of these 3 measurements was taken per time point. MMRM has been calculated but did not provide estimates for this time point due to low sample size. Thus, change in sitting height from baseline to Week 52 was analyzed descriptively only.

Time frame:
Measurements were assessed at Week 0 and at Week 52
Reported as:
Mean · Centimeters
Absolute Change From Baseline in Sitting Height at Week 52
CentimetersDBP + OLNP: Randomised to PlaceboDBP + OLNP: Randomised to Nintedanib
At Baseline78.7 ± 11.877.6 ± 9.4
At Week 5279.0 ± 12.279.3 ± 8.6
SecondaryAbsolute Change From Baseline in Sitting Height at Week 76

Absolute change from baseline in sitting height at Week 76 was measured with a stadiometer 3 times at each time point. The average of these 3 measurements was take per time point. MMRM has been calculated but did not provide estimates for this time point due to low sample size. Thus, change in sitting height from baseline to Week 76 was analyzed descriptively only.

Time frame:
Measurements were assessed at Week 0 and at Week 76
Reported as:
Mean · Centimeters
Absolute Change From Baseline in Sitting Height at Week 76
CentimetersDBP + OLNP: Randomised to PlaceboDBP+OLNP: Randomised to Nintedanib
At Baseline65.0 ± NA83.0 ± 4.2
At Week 7665.0 ± NA84.5 ± 3.5
SecondaryAbsolute Change From Baseline in Leg Length at Week 24 - Left

Absolute change from baseline in left leg length at Week 24 was assessed by measuring the distance between the anterior iliac spine and the medial malleolus 3 times at each leg and each time point. The average of these 3 measurements was taken per time point. Absolute change from baseline in left leg length at Week 24 in the treated set (TS) was based on a Mixed Model Repeated Measures (MMRM), with fixed categorical effects of (randomised) treatment at each visit, age-group and the fixed continuous effects of baseline at each visit, and random effect for participant. Visit was treated as the repeated measure with an unstructured covariance structure used to model the within-participant measurements.

Time frame:
MMRM included measurements at 0, 12, 24, 36, 52, 64, and 76 weeks after first drug administration. MMRM values at Week 24 are reported in the table below
Reported as:
Least squares mean · Centimeters
Absolute Change From Baseline in Leg Length at Week 24 - Left
CentimetersDBP: Randomised to PlaceboDBP: Randomised to Nintedanib
Absolute Change From Baseline in Leg Length at Week 24 - Left1.6 (0.3 to 2.9)1.7 (0.8 to 2.7)
Statistical analysis
  • DBP: Randomised to Placebo vs DBP: Randomised to Nintedanib · Mixed Model Repeated Measures (MMRM) · p = 0.8820 · Adjusted mean difference: 0.1 · 95% CI -1.5 to 1.8Adjusted mean difference was calculated as 'Randomised Nintedanib - randomised placebo'.
SecondaryAbsolute Change From Baseline in Leg Length at Week 52 - Left

Absolute change from baseline in left leg length at Week 52 was assessed by measuring the distance between the anterior iliac spine and the medial malleolus 3 times at each leg and each time point. The average of these 3 measurements was taken per time point. Absolute change from baseline in left leg length at Week 52 in the treated set (TS) was based on a Mixed Model Repeated Measures (MMRM), with fixed categorical effects of (randomised) treatment at each visit, age-group and the fixed continuous effects of baseline at each visit, and random effect for participant. Visit was treated as the repeated measure with an unstructured covariance structure used to model the within-participant measurements.

Time frame:
MMRM included measurements at 0, 12, 24, 36, 52, 64, and 76 weeks after first drug administration. MMRM values at Week 52 are reported in the table below
Reported as:
Least squares mean · Centimeter
Absolute Change From Baseline in Leg Length at Week 52 - Left
CentimeterDBP+OLNP: Randomised to PlaceboDBP+OLNP: Randomised to Nintedanib
Absolute Change From Baseline in Leg Length at Week 52 - Left2.8 (0.3 to 5.4)2.9 (0.9 to 4.9)
Statistical analysis
  • DBP+OLNP: Randomised to Placebo vs DBP+OLNP: Randomised to Nintedanib · Mixed Model Repeated Measures (MMRM) · p = 0.9652 · Adjusted mean difference: 0.1 · 95% CI -3.2 to 3.3Adjusted mean difference was calculated as 'Randomised Nintedanib - randomised placebo'.
SecondaryAbsolute Change From Baseline in Leg Length at Week 76 - Left

Absolute change from baseline in left leg length at Week 76 was assessed by measuring the distance between the anterior iliac spine and the medial malleolus 3 times at each leg and each time point. The average of these 3 measurements was taken per time point. Absolute change from baseline in left leg length at Week 76 in the treated set (TS) was based on a Mixed Model Repeated Measures (MMRM), with fixed categorical effects of (randomised) treatment at each visit, age-group and the fixed continuous effects of baseline at each visit, and random effect for participant. Visit was treated as the repeated measure with an unstructured covariance structure used to model the within-participant measurements.

Time frame:
MMRM included measurements at 0, 12, 24, 36, 52, 64, and 76 weeks after first drug administration. MMRM values at Week 76 are reported in the table below
Reported as:
Least squares mean · Centimeter
Absolute Change From Baseline in Leg Length at Week 76 - Left
CentimeterDBP+OLNP: Randomised to PlaceboDBP+OLNP: Randomised to Nintedanib
Absolute Change From Baseline in Leg Length at Week 76 - Left5.2 (-0.0 to 10.5)2.6 (-1.5 to 6.7)
Statistical analysis
  • DBP+OLNP: Randomised to Placebo vs DBP+OLNP: Randomised to Nintedanib · Mixed Model Repeated Measures (MMRM) · p = 0.4084 · Adjusted mean difference: -2.6 · 95% CI -9.3 to 4.0Adjusted mean difference was calculated as 'Randomised Nintedanib - randomised placebo'.
SecondaryAbsolute Change From Baseline in Leg Length at Week 24 - Right

Absolute change from baseline in right leg length at Week 24 was assessed by measuring the distance between the anterior iliac spine and the medial malleolus 3 times at each leg and each time point. The average of these 3 measurements was taken per time point. Absolute change from baseline in right leg length at Week 24 in the treated set (TS) was based on a Mixed Model Repeated Measures (MMRM), with fixed categorical effects of (randomised) treatment at each visit, age-group and the fixed continuous effects of baseline at each visit, and random effect for participant. Visit was treated as the repeated measure with an unstructured covariance structure used to model the within-participant measurements.

Time frame:
MMRM included measurements at 0, 12, 24, 36, 52, 64, and 76 weeks after first drug administration. MMRM values at Week 24 are reported in the table below
Reported as:
Least squares mean · Centimeters
Absolute Change From Baseline in Leg Length at Week 24 - Right
CentimetersDBP: Randomised to PlaceboDBP: Randomised to Nintedanib
Absolute Change From Baseline in Leg Length at Week 24 - Right1.6 (0.3 to 2.9)1.6 (0.6 to 2.6)
Statistical analysis
  • DBP: Randomised to Placebo vs DBP: Randomised to Nintedanib · Mixed Model Repeated Measures (MMRM) · p = 0.9928 · Adjusted mean difference: 0.0 · 95% CI -1.6 to 1.6Adjusted mean difference was calculated as 'Randomised Nintedanib - randomised placebo'.
SecondaryAbsolute Change From Baseline in Leg Length at Week 52 - Right

Absolute change from baseline in right leg length at Week 52 was assessed by measuring the distance between the anterior iliac spine and the medial malleolus 3 times at each leg and each time point. The average of these 3 measurements was taken per time point. Absolute change from baseline in right leg length at Week 52 in the treated set (TS) was based on a Mixed Model Repeated Measures (MMRM), with fixed categorical effects of (randomised) treatment at each visit, age-group and the fixed continuous effects of baseline at each visit, and random effect for participant. Visit was treated as the repeated measure with an unstructured covariance structure used to model the within-participant measurements.

Time frame:
MMRM included measurements at 0, 12, 24, 36, 52, 64, and 76 weeks after first drug administration. MMRM values at Week 52 are reported in the table below
Reported as:
Least squares mean · Centimeter
Absolute Change From Baseline in Leg Length at Week 52 - Right
CentimeterDBP+OLNP: Randomised to PlaceboDBP+OLNP: Randomised to Nintedanib
Absolute Change From Baseline in Leg Length at Week 52 - Right2.8 (0.4 to 5.1)3.4 (1.6 to 5.2)
Statistical analysis
  • DBP+OLNP: Randomised to Placebo vs DBP+OLNP: Randomised to Nintedanib · Mixed Model Repeated Measures (MMRM) · p = 0.6366 · Adjusted mean difference: 0.7 · 95% CI -2.3 to 3.6Adjusted mean difference was calculated as 'Randomised Nintedanib - randomised placebo'.
SecondaryAbsolute Change From Baseline in Leg Length at Week 76 - Right

Absolute change from baseline in right leg length at Week 76 was assessed by measuring the distance between the anterior iliac spine and the medial malleolus 3 times at each leg and each time point. The average of these 3 measurements was taken per time point. Absolute change from baseline in right leg length at Week 76 in the treated set (TS) was based on a Mixed Model Repeated Measures (MMRM), with fixed categorical effects of (randomised) treatment at each visit, age-group and the fixed continuous effects of baseline at each visit, and random effect for participant. Visit was treated as the repeated measure with an unstructured covariance structure used to model the within-participant measurements.

Time frame:
MMRM included measurements at 0, 12, 24, 36, 52, 64, and 76 weeks after first drug administration. MMRM values at Week 76 are reported in the table below
Reported as:
Least squares mean · Centimeter
Absolute Change From Baseline in Leg Length at Week 76 - Right
CentimeterDBP+OLNP: Randomised to PlaceboDBP+OLNP: Randomised to Nintedanib
Absolute Change From Baseline in Leg Length at Week 76 - Right3.9 (-0.5 to 8.3)4.3 (0.8 to 7.7)
Statistical analysis
  • DBP+OLNP: Randomised to Placebo vs DBP+OLNP: Randomised to Nintedanib · Mixed Model Repeated Measures (MMRM) · p = 0.8823 · Adjusted mean difference: 0.4 · 95% CI -5.2 to 5.9Adjusted mean difference was calculated as 'Randomised Nintedanib - randomised placebo'.
SecondaryAbsolute Change From Baseline in Forced Vital Capacity (FVC) % Predicted at Week 24

Forced Vital Capacity (FVC) is the volume of air (measured in milliliter) which can be forcibly exhaled from the lungs after taking the deepest breath possible. The predicted values were calculated according to the Global Lungs Initiative (GLI) 2012 equations. Absolute change from baseline in Forced Vital Capacity (FVC) % predicted at Week 24 in the treated set(TS) was based on a Mixed Model Repeated Measures (MMRM), with fixed categorical effects of (randomised) treatment at each visit, age-group and the fixed continuous effects of baseline at each visit, and random effect for participant. Visit was treated as the repeated measure with an unstructured covariance structure used to model the within-participant measurements.

Time frame:
MMRM included measurements pre-administration at -4 weeks and at 0, 2, 6, 12, 24, 26, 36, and 52 weeks after first drug administration. MMRM values at Week 24 are reported in the table below
Reported as:
Least squares mean · Percentage of predicted FVC
Absolute Change From Baseline in Forced Vital Capacity (FVC) % Predicted at Week 24
Percentage of predicted FVCDBP: Randomised to PlaceboDBP: Randomised to Nintedanib
Absolute Change From Baseline in Forced Vital Capacity (FVC) % Predicted at Week 24-0.8939 (-4.6090 to 2.8211)0.3112 (-2.3595 to 2.9820)
Statistical analysis
  • DBP: Randomised to Placebo vs DBP: Randomised to Nintedanib · Mixed Model Repeated Measures (MMRM) · p = 0.5962 · Adjusted mean difference: 1.2052 · 95% CI -3.3966 to 5.8070Adjusted mean difference was calculated as 'Randomised Nintedanib - randomised placebo'.
SecondaryAbsolute Change From Baseline in Forced Vital Capacity (FVC) % Predicted at Week 52

Forced Vital Capacity (FVC) is the volume of air (measured in milliliter) which can be forcibly exhaled from the lungs after taking the deepest breath possible. The predicted values were calculated according to the Global Lungs Initiative (GLI) 2012 equations. Absolute change from baseline in Forced Vital Capacity (FVC) % predicted at Week 52 in the treated set(TS) was based on a Mixed Model Repeated Measures (MMRM), with fixed categorical effects of (randomised) treatment at each visit, age-group and the fixed continuous effects of baseline at each visit, and random effect for participant. Visit was treated as the repeated measure with an unstructured covariance structure used to model the within-participant measurements.

Time frame:
MMRM included measurements pre-administration at -4 weeks and at 0, 2, 6, 12, 24, 26, 36, and 52 weeks after first drug administration. MMRM values at Week 52 are reported in the table below
Reported as:
Least squares mean · Percentage of predicted FVC
Absolute Change From Baseline in Forced Vital Capacity (FVC) % Predicted at Week 52
Percentage of predicted FVCDBP+OLNP: Randomised to PlaceboDBP + OLNP: Randomised to Nintedanib
Absolute Change From Baseline in Forced Vital Capacity (FVC) % Predicted at Week 52-0.9827 (-6.2611 to 4.2958)0.7906 (-2.9464 to 4.5277)
Statistical analysis
  • DBP+OLNP: Randomised to Placebo vs DBP + OLNP: Randomised to Nintedanib · Mixed Model Repeated Measures (MMRM) · p = 0.5776 · Adjusted mean difference: 1.7733 · 95% CI -4.7015 to 8.2481Adjusted mean difference was calculated as 'Randomised Nintedanib - randomised placebo'.
SecondaryAbsolute Change From Baseline in Pediatric Quality of Life Questionnaire™(PedsQL™) at Week 24 - Parent Report

The PedsQL™ questionnaires consists of 23 items (i) and 4 dimensions: physical (8i), emotional (5i), social (5i) and school (5i) functioning. A 5-point Likert response scale (0 = never (worst outcome) to 4=almost always (best outcome)) was used except for the Young Child Report, where a 3-point scale (0=not at all (worst outcome) to 4=a lot (best outcome)) was used. Items were reverse-scored and linearly transformed to a 0-100 scale (0 = 100 to 4 = 0). Higher scores indicated better health-related quality of life. To create total scores, the mean was computed. Absolute change from baseline in PedsQL™ reported by parents was based on a Mixed Model Repeated Measures (MMRM), with fixed categorical effects of (randomised) treatment at each visit, age-group and the fixed continuous effects of baseline at each visit, and random effect for participant. Visit was treated as the repeated measure with an unstructured covariance structure used to model the within-participant measurements.

Time frame:
MMRM included measurements at 0, 24, and 52 weeks after first drug administration. MMRM values at Week 24 are reported in the table below
Reported as:
Least squares mean · Unit on scale
Absolute Change From Baseline in Pediatric Quality of Life Questionnaire™(PedsQL™) at Week 24 - Parent Report
Unit on scaleDBP: Randomised to PlaceboDBP: Randomised to Nintedanib
Absolute Change From Baseline in Pediatric Quality of Life Questionnaire™(PedsQL™) at Week 24 - Parent Report5.615 (-1.506 to 12.736)5.481 (0.384 to 10.578)
Statistical analysis
  • DBP: Randomised to Placebo vs DBP: Randomised to Nintedanib · Mixed Model Repeated Measures (MMRM) · p = 0.9755 · Adjusted mean difference: -0.134 · 95% CI -8.975 to 8.707Adjusted mean difference was calculated as 'Randomised Nintedanib - randomised placebo'.
SecondaryAbsolute Change From Baseline in Pediatric Quality of Life Questionnaire™(PedsQL™) at Week 52 - Parent Report

The PedsQL™ questionnaires consists of 23 items (i) and 4 dimensions: physical (8i), emotional (5i), social (5i) and school (5i) functioning. A 5-point Likert response scale (0 = never (worst outcome) to 4=almost always (best outcome)) was used except for the Young Child Report, where a 3-point scale (0=not at all (worst outcome) to 4=a lot (best outcome)) was used. Items were reverse-scored and linearly transformed to a 0-100 scale (0 = 100 to 4 = 0). Higher scores indicated better health-related quality of life. To create total scores, the mean was computed. Absolute change from baseline in PedsQL™ reported by parents was based on a Mixed Model Repeated Measures (MMRM), with fixed categorical effects of (randomised) treatment at each visit, age-group and the fixed continuous effects of baseline at each visit, and random effect for participant. Visit was treated as the repeated measure with an unstructured covariance structure used to model the within-participant measurements.

Time frame:
MMRM included measurements at 0, 24, and 52 weeks after first drug administration. MMRM values at Week 52 are reported in the table below
Reported as:
Least squares mean · Unit on scale
Absolute Change From Baseline in Pediatric Quality of Life Questionnaire™(PedsQL™) at Week 52 - Parent Report
Unit on scaleDBP+OLNP: Randomised to PlaceboDBP+OLNP: Randomised to Nintedanib
Absolute Change From Baseline in Pediatric Quality of Life Questionnaire™(PedsQL™) at Week 52 - Parent Report4.377 (-4.403 to 13.157)7.830 (1.799 to 13.862)
Statistical analysis
  • DBP+OLNP: Randomised to Placebo vs DBP+OLNP: Randomised to Nintedanib · Mixed Model Repeated Measures (MMRM) · p = 0.5140 · Adjusted mean difference: 3.453 · 95% CI -7.250 to 14.157Adjusted mean difference was calculated as 'Randomised Nintedanib - randomised placebo'.
SecondaryAbsolute Change From Baseline in Pediatric Quality of Life Questionnaire™(PedsQL™) at Week 24 - Participant Report

The PedsQL™ questionnaires consists of 23 items (i) and 4 dimensions: physical (8i), emotional (5i), social (5i) and school (5i) functioning. A 5-point Likert response scale (0 = never (worst outcome) to 4=almost always (best outcome)) was used except for the Young Child Report, where a 3-point scale (0=not at all (worst outcome) to 4=a lot (best outcome)) was used. Items were reverse-scored and linearly transformed to a 0-100 scale (0 = 100 to 4 = 0). Higher scores indicated better health-related quality of life. To create total scores, the mean was computed. Absolute change from baseline in PedsQL™ was based on a Mixed Model Repeated Measures (MMRM), with fixed categorical effects of (randomised) treatment at each visit, age-group and the fixed continuous effects of baseline at each visit, and random effect for participant. Visit was treated as the repeated measure with an unstructured covariance structure used to model the within-participant measurements.

Time frame:
MMRM included measurements at 0, 24, and 52 weeks after first drug administration. MMRM values at Week 24 are reported in the table below
Reported as:
Least squares mean · Unit on scale
Absolute Change From Baseline in Pediatric Quality of Life Questionnaire™(PedsQL™) at Week 24 - Participant Report
Unit on scaleDBP: Randomised to PlaceboDBP: Randomised to Nintedanib
Absolute Change From Baseline in Pediatric Quality of Life Questionnaire™(PedsQL™) at Week 24 - Participant Report5.484 (-0.051 to 11.018)6.514 (2.531 to 10.497)
Statistical analysis
  • DBP: Randomised to Placebo vs DBP: Randomised to Nintedanib · Mixed Model Repeated Measures (MMRM) · p = 0.7613 · Adjusted mean difference: 1.030 · 95% CI -5.848 to 7.908Adjusted mean difference was calculated as 'Randomised Nintedanib - randomised placebo'.
SecondaryAbsolute Change From Baseline in Pediatric Quality of Life Questionnaire™(PedsQL™) at Week 52 - Participant Report

The PedsQL™ questionnaires consists of 23 items (i) and 4 dimensions: physical (8i), emotional (5i), social (5i) and school (5i) functioning. A 5-point Likert response scale (0 = never (worst outcome) to 4=almost always (best outcome)) was used except for the Young Child Report, where a 3-point scale (0=not at all (worst outcome) to 4=a lot (best outcome)) was used. Items were reverse-scored and linearly transformed to a 0-100 scale (0 = 100 to 4 = 0). Higher scores indicated better health-related quality of life. To create total scores, the mean was computed. Absolute change from baseline in PedsQL™ was based on a Mixed Model Repeated Measures (MMRM), with fixed categorical effects of (randomised) treatment at each visit, age-group and the fixed continuous effects of baseline at each visit, and random effect for participant. Visit was treated as the repeated measure with an unstructured covariance structure used to model the within-participant measurements.

Time frame:
MMRM included measurements at 0, 24, and 52 weeks after first drug administration. MMRM values at Week 52 are reported in the table below
Reported as:
Least squares mean · Unit on scale
Absolute Change From Baseline in Pediatric Quality of Life Questionnaire™(PedsQL™) at Week 52 - Participant Report
Unit on scaleDBP+OLNP: Randomised to PlaceboDBP+OLNP: Randomised to Nintedanib
Absolute Change From Baseline in Pediatric Quality of Life Questionnaire™(PedsQL™) at Week 52 - Participant Report0.902 (-7.616 to 9.420)1.243 (-4.598 to 7.083)
Statistical analysis
  • DBP+OLNP: Randomised to Placebo vs DBP+OLNP: Randomised to Nintedanib · Mixed Model Repeated Measures (MMRM) · p = 0.9468 · Adjusted mean difference: 0.340 · 95% CI -10.026 to 10.707Adjusted mean difference was calculated as 'Randomised Nintedanib - randomised placebo'.
SecondaryAbsolute Change From Baseline in Oxygen Saturation (SpO₂) on Room Air at Rest at Week 24

Oxygen saturation (SpO₂) was measured after minimum 5 minutes on room air by standard pulse oximetry at rest. Absolute change from baseline in SpO₂ at Week 24 in the treated set(TS) was based on a Mixed Model Repeated Measures (MMRM), with fixed categorical effects of (randomised) treatment at each visit, age-group and the fixed continuous effects of baseline at each visit, and random effect for participant. Visit was treated as the repeated measure with an unstructured covariance structure used to model the within-participant measurements.

Time frame:
MMRM included measurements pre-administration at -4 weeks and at 0, 2, 6, 12, 24, 26, 36, and 52 weeks after first drug administration. MMRM values at Week 24 are reported in the table below
Reported as:
Least squares mean · Percentage of SpO₂
Absolute Change From Baseline in Oxygen Saturation (SpO₂) on Room Air at Rest at Week 24
Percentage of SpO₂DBP: Randomised to PlaceboDBP: Randomised to Nintedanib
Absolute Change From Baseline in Oxygen Saturation (SpO₂) on Room Air at Rest at Week 24-2.25 (-4.45 to -0.04)0.07 (-1.49 to 1.63)
Statistical analysis
  • DBP: Randomised to Placebo vs DBP: Randomised to Nintedanib · Mixed Model Repeated Measures (MMRM) · p = 0.0908 · Adjusted mean difference: 2.31 · 95% CI -0.39 to 5.02Adjusted mean difference was calculated as 'Randomised Nintedanib - randomised placebo'.
SecondaryAbsolute Change From Baseline in Oxygen Saturation (SpO₂) on Room Air at Rest at Week 52

Oxygen saturation (SpO₂) was measured after minimum 5 minutes on room air by standard pulse oximetry at rest. Absolute change from baseline in SpO₂ at Week 52 in the treated set(TS) was based on a Mixed Model Repeated Measures (MMRM), with fixed categorical effects of (randomised) treatment at each visit, age-group and the fixed continuous effects of baseline at each visit, and random effect for participant. Visit was treated as the repeated measure with an unstructured covariance structure used to model the within-participant measurements.

Time frame:
MMRM included measurements pre-administration at -4 weeks and at 0, 2, 6, 12, 24, 26, 36, and 52 weeks after first drug administration. MMRM values at Week 52 are reported in the table below
Reported as:
Least squares mean · Percentage of SpO₂
Absolute Change From Baseline in Oxygen Saturation (SpO₂) on Room Air at Rest at Week 52
Percentage of SpO₂DBP+OLNP: Randomised to PlaceboDBP+OLNP: Randomised to Nintedanib
Absolute Change From Baseline in Oxygen Saturation (SpO₂) on Room Air at Rest at Week 52-2.60 (-5.02 to -0.18)-0.32 (-2.03 to 1.40)
Statistical analysis
  • DBP+OLNP: Randomised to Placebo vs DBP+OLNP: Randomised to Nintedanib · Mixed Model Repeated Measures (MMRM) · p = 0.1222 · Adjusted mean difference: 2.28 · 95% CI -0.69 to 5.25Adjusted mean difference was calculated as 'Randomised Nintedanib - randomised placebo'.
SecondaryAbsolute Change From Baseline in 6 Minutes (Min) Walk Distance at Week 24

Absolute change from baseline in 6 minutes (min) walk distance at Week 24 in the treated set (TS) was based on a Mixed Model Repeated Measures (MMRM), with fixed categorical effects of (randomised) treatment at each visit, age-group and the fixed continuous effects of baseline at each visit, and random effect for participant. Visit was treated as the repeated measure with an unstructured covariance structure used to model the within-participant measurements.

Time frame:
MMRM included measurements at 0, 24, and 52 weeks after first drug administration. MMRM values at Week 24 are reported in the table below
Reported as:
Least squares mean · Meter
Absolute Change From Baseline in 6 Minutes (Min) Walk Distance at Week 24
MeterDBP: Randomised to PlaceboDBP: Randomised to Nintedanib
Absolute Change From Baseline in 6 Minutes (Min) Walk Distance at Week 2410.5 (-36.4 to 57.3)17.6 (-16.2 to 51.5)
Statistical analysis
  • DBP: Randomised to Placebo vs DBP: Randomised to Nintedanib · Mixed Model Repeated Measures (MMRM) · p = 0.8012 · Adjusted mean difference: 7.2 · 95% CI -50.7 to 65.0Adjusted mean difference was calculated as 'Randomised Nintedanib - randomised placebo'.
SecondaryAbsolute Change From Baseline in 6 Minutes (Min) Walk Distance at Week 52

Absolute change from baseline in 6 minutes (min) walk distance at Week 52 in the treated set(TS) was based on a Mixed Model Repeated Measures (MMRM), with fixed categorical effects of (randomised) treatment at each visit, age-group and the fixed continuous effects of baseline at each visit, and random effect for participant. Visit was treated as the repeated measure with an unstructured covariance structure used to model the within-participant measurements.

Time frame:
MMRM included measurements at 0, 24, and 52 weeks after first drug administration. MMRM values at Week 52 are reported in the table below
Reported as:
Least squares mean · Meter (m)
Absolute Change From Baseline in 6 Minutes (Min) Walk Distance at Week 52
Meter (m)DBP+OLNP: Randomised to PlaceboDBP+OLNP: Randomised Nintedanib
Absolute Change From Baseline in 6 Minutes (Min) Walk Distance at Week 5228.1 (-29.4 to 85.5)-4.9 (-44.5 to 34.7)
Statistical analysis
  • DBP+OLNP: Randomised to Placebo vs DBP+OLNP: Randomised Nintedanib · Mixed Model Repeated Measures (MMRM) · p = 0.3401 · Adjusted mean difference: -32.9 · 95% CI -103.1 to 37.2Adjusted mean difference was calculated as 'Randomised Nintedanib - randomised placebo'.
SecondaryParticipants Acceptability Based on the Size of Capsules at Week 24 - Patient Question

Acceptability is defined as the overall ability and willingness of the participant to use the medicinal product as intended. Acceptability based on the capsule size was assessed by a acceptability questionnaire (1 item with 3 categories as shown below) for participants. In case the participant was considered not old enough as per investigator judgment the caregiver could assist with the completion. In addition to the commercially available 100 milligram (mg) soft capsules (oblong shape, 6 millimeter (mm) diameter and 16 mm length) and 150 mg soft capsules (oblong shape, 7 mm diameter and 18 mm length), 25 mg Nintedanib soft capsules of smaller size (oval shape, 5 mm diameter and 8 mm length) were provided in this trial for participants who were assigned to a dose smaller than 100 mg or were unable to swallow the larger 100 mg or 150 mg capsules.

Time frame:
Acceptability was assessed at Week 24
Reported as:
Count of participants · Participants
Participants Acceptability Based on the Size of Capsules at Week 24 - Patient Question
ParticipantsDBP: Randomised to Placebo - Capsule Size of 25 mg CapsuleDBP: Randomised to Nintedanib - Capsule Size of 25 mg CapsuleDBP: Randomised to Placebo - Capsule Size of 100 mg CapsuleDBP: Randomised to Nintedanib - Capsule Size of 100 mg CapsuleDBP: Randomised to Placebo - Capsule Size of 150 mg CapsuleDBP: Randomised to Nintedanib - Capsule Size of 150 mg Capsule
OK4641432
Large000000
Very Large000000
SecondaryParticipants Acceptability Based on the Size of Capsules at Week 24 - Investigator Question

Acceptability is defined as the overall ability and willingness of the participant to use the medicinal product as intended. Acceptability based on the capsule size was assessed by a acceptability questionnaire (1 item with 3 categories as shown below) for investigators. In addition to the commercially available 100 milligram (mg) soft capsules (oblong shape, 6 millimeter (mm) diameter and 16 mm length) and 150 mg soft capsules (oblong shape, 7 mm diameter and 18 mm length), 25 mg Nintedanib soft capsules of smaller size (oval shape, 5 mm diameter and 8 mm length) were provided in this trial for participants who were assigned to a dose smaller than 100 mg or were unable to swallow the larger 100 mg or 150 mg capsules.

Time frame:
Acceptability was assessed at Week 24
Reported as:
Count of participants · Participants
Participants Acceptability Based on the Size of Capsules at Week 24 - Investigator Question
ParticipantsDBP: Randomised to Placebo - Capsule Size of 25 mg CapsuleDBP: Randomised to Nintedanib - Capsule Size of 25 mg CapsuleDBP: Randomised to Placebo - Capsule Size of 100 mg CapsuleDBP: Randomised to Nintedanib - Capsule Size of 100 mg CapsuleDBP: Randomised to Placebo - Capsule Size of 150 mg CapsuleDBP: Randomised to Nintedanib - Capsule Size of 150 mg Capsule
No121201
Yes000000
Missing3431231
SecondaryParticipants Acceptability Based on the Number of Capsules at Week 24 - Patient Question

Acceptability is defined as the overall ability and willingness of the participant to use the medicinal product as intended. Acceptability based on the number of capsule was assessed by a acceptability questionnaire (1 item with 3 categories as shown below) for participants. In case the participant was considered not old enough as per investigator judgment the caregiver could assist with the completion. In addition to the commercially available 100 milligram (mg) soft capsules (oblong shape, 6 millimeter (mm) diameter and 16 mm length) and 150 mg soft capsules (oblong shape, 7 mm diameter and 18 mm length), 25 mg Nintedanib soft capsules of smaller size (oval shape, 5 mm diameter and 8 mm length) were provided in this trial for participants who were assigned to a dose smaller than 100 mg or were unable to swallow the larger 100 mg or 150 mg capsules. Medication dosage was based on the participant's body weight and number of capsules per administration ranged from 2 to \>6 capsules.

Time frame:
Acceptability was assessed at Week 24
Reported as:
Count of participants · Participants
Participants Acceptability Based on the Number of Capsules at Week 24 - Patient Question
ParticipantsDBP: Randomised to Placebo - 2 CapsulesDBP: Randomised to Nintedanib - 2 CapsulesDBP: Randomised to Placebo - 4 CapsulesDBP: Randomised to Nintedanib - 4 CapsulesDBP: Randomised to Placebo - 6 CapsulesDBP: Randomised to Nintedanib - 6 CapsulesDBP: Randomised to Placebo - >6 CapsulesDBP: Randomised to Nintedanib - >6 Capsules
I had no problem swallowing them716231310
I swallowed them but it was difficult00000000
I could not swallow them sometimes00000000
SecondaryNumber of Participants With Occurrence of First Respiratory-related Hospitalization Over the Whole Trial

Number of participants with occurrence of first respiratory-related hospitalization over the whole trial. The number of participants with first respiratory-related hospitalization is reported instead of a metric summarizing the time-to-event data with unit of time, as the numbers resulting from the Kaplan-Meier-analysis were even below the first quartile.

Time frame:
From first drug administration until the last drug intake + 28 days residual effect period (REP), up to 92.6 weeks
Reported as:
Count of participants · Participants
Number of Participants With Occurrence of First Respiratory-related Hospitalization Over the Whole Trial
ParticipantsDBP+OLNP: Randomised to PlaceboDBP+OLNP: Randomised to Nintedanib
Number of Participants With Occurrence of First Respiratory-related Hospitalization Over the Whole Trial03
SecondaryNumber of Participants With Occurrence of First Acute Interstitial Lung Disease (ILD) Exacerbation or Death Over the Whole Trial

Number of participants with occurrence of first acute Interstitial Lung Disease (ILD) exacerbation or death over the whole trial. The number of participants with first acute ILD exacerbation is reported instead of a metric summarizing the time-to-event data with unit of time, as the numbers resulting from the Kaplan-Meier-analysis were even below the first quartile.

Time frame:
From first drug administration until the last drug intake + 28 days REP, up to 92.6 weeks
Reported as:
Count of participants · Participants
Number of Participants With Occurrence of First Acute Interstitial Lung Disease (ILD) Exacerbation or Death Over the Whole Trial
ParticipantsDBP+OLNP: Randomised to PlaceboDBP+OLNP: Randomised to Nintedanib
Number of Participants With Occurrence of First Acute Interstitial Lung Disease (ILD) Exacerbation or Death Over the Whole Trial02
SecondaryNumber of Participants With Occurrence of Death Over the Whole Trial

Number of participants with occurrence of death over the whole trial over the whole trial was computed. The number of participants with occurrence of death is reported instead of a metric summarizing the time-to-event data with unit of time, as the numbers resulting from the Kaplan-Meier-analysis were even below the first quartile.

Time frame:
From first drug administration until the last drug intake + 28 days REP, up to 92.6 weeks
Reported as:
Count of participants · Participants
Number of Participants With Occurrence of Death Over the Whole Trial
ParticipantsDBP+OLNP: Randomised to PlaceboDBP+OLNP: Randomised to Nintedanib
Number of Participants With Occurrence of Death Over the Whole Trial00

Adverse events

Collected over Placebo-randomised DBP: From treatment start till end of DBP (defined as the day before first intake of open-label nintedanib (NIN) or last double-blind drug intake, up to 24.4 weeks + 28 days (REP), whichever is earlier) Placebo-randomised OLNP: From first intake of NIN till last intake of the OLNP, up to 64.6 weeks + 28 days (REP). Nintedanib-randomised DBP+OLNP: From first intake of NIN (DBP / OLNP) till last intake of NIN (DBP or OLNP), up to 85.1 weeks + 28 days (REP).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
DBP: Randomised to Placebo0/13 (0%)1/13 (7.7%)11/13 (84.6%)
OLNP: Randomised to Placebo and Switched to Nintedanib0/11 (0%)2/11 (18.2%)11/11 (100%)
DBP+OLNP: Randomised to Nintedanib (Nintedanib Exposure Period)0/26 (0%)5/26 (19.2%)26/26 (100%)
Most frequent serious events
Most frequent serious events
EventDBP: Randomised to PlaceboOLNP: Randomised to Placebo and Switched to NintedanibDBP+OLNP: Randomised to Nintedanib (Nintedanib Exposure Period)
Drug-induced liver injuryHepatobiliary disorders0/131/110/26
Neurogenic shockVascular disorders0/131/110/26
COVID-19Infections and infestations0/130/112/26
Frontal lobe epilepsyNervous system disorders1/130/110/26
Tooth development disorderGastrointestinal disorders0/130/111/26
Liver injuryHepatobiliary disorders0/130/111/26
Carbon dioxide increasedInvestigations0/130/111/26
Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders0/130/111/26
Respiratory distressRespiratory, thoracic and mediastinal disorders0/130/111/26
Most frequent other events
Showing 10 of 63
Most frequent other events
EventDBP: Randomised to PlaceboOLNP: Randomised to Placebo and Switched to NintedanibDBP+OLNP: Randomised to Nintedanib (Nintedanib Exposure Period)
DiarrhoeaGastrointestinal disorders2/136/1112/26
NauseaGastrointestinal disorders3/136/116/26
Abdominal painGastrointestinal disorders3/134/116/26
VomitingGastrointestinal disorders3/134/117/26
CoughRespiratory, thoracic and mediastinal disorders1/133/110/26
Dental cariesGastrointestinal disorders3/131/117/26
COVID-19Infections and infestations1/131/117/26
Tooth development disorderGastrointestinal disorders1/130/116/26
Chest painGeneral disorders0/132/112/26
NasopharyngitisInfections and infestations1/132/111/26

Baseline characteristics

Treated set (TS): The TS consisted of participants who were randomised to a treatment group and received at least one dose of study medication.

Age, Continuous
Age, Continuous(Years)DBP+OLNP: Randomised to PlaceboDBP+OLNP: Randomised to NintedanibTotal
Mean12.9 ± 2.812.5 ± 3.612.6 ± 3.3
Sex: Female, Male
Sex: Female, Male(Participants)DBP+OLNP: Randomised to PlaceboDBP+OLNP: Randomised to NintedanibTotal
Female51015
Male81624
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)DBP+OLNP: Randomised to PlaceboDBP+OLNP: Randomised to NintedanibTotal
Hispanic or Latino5712
Not Hispanic or Latino81826
Unknown or Not Reported011
Race (NIH/OMB)
Race (NIH/OMB)(Participants)DBP+OLNP: Randomised to PlaceboDBP+OLNP: Randomised to NintedanibTotal
American Indian or Alaska Native112
Asian022
Native Hawaiian or Other Pacific Islander000
Black or African American033
White121931
More than one race000
Unknown or Not Reported011
08

Study locations

43 sites
  • Children's Hospital Los Angeles
    Los Angeles, California 90027, United States
  • Children's Hospital Colorado
    Aurora, Colorado 80045, United States
  • Riley Hospital for Children at Indiana University Health
    Indianapolis, Indiana 46202, United States
  • Children's Mercy Hospitals and Clinics
    Kansas City, Missouri 64108, United States
  • Weill Cornell Medicine
    New York, New York 10021, United States
  • Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • Children's Hospital of Pittsburgh of University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15224, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • Seattle Children's Hospital
    Seattle, Washington 98105, United States
  • Hospital de Pediatría " Prof. Dr. Juan P. Garrahan"
    Caba, C1245AAM, Argentina
  • Hospital de Niños Dr. Ricardo Gutierrez
    Caba, C1425EFD, Argentina
  • INSARES
    Mendoza, M5500CCG, Argentina
  • Women's and Children's Hospital
    North Adelaide, South Australia 5006, Australia
  • Brussels - UNIV HUDERF
    Bruxelles, 1020, Belgium
  • Serviços Medicos Respirar Sul Fluminense
    Barra Mansa, 27323240, Brazil
  • Centro de Pesquisa Clinica do Instituto da Crianca - HCFMUSP
    Sao Paulo, 5403-900, Brazil
  • BC Children's Hospital
    Vancouver, British Columbia V6H 3N1, Canada
  • The Hospital for Sick Children
    Toronto, Ontario M5G 1X8, Canada
  • Teaching Hospital Motol, Oncology Clinic
    Praha 5, 150 06, Czechia
  • Aarhus University Hospital
    Aarhus N, 8200, Denmark
  • Tampere University Hospital
    Tampere, 33520, Finland
  • HOP Intercommunal
    Créteil, 94010, France
  • HOP Armand-Trousseau
    Paris, 75571, France
  • General Hospital of Thessaloniki "Ippokrateio"
    Thessaloniki, 54642, Greece
  • Semmelweis University
    Budapest, 1122, Hungary
  • Azienda Ospedaliera Meyer
    Firenze, 50139, Italy
  • Azienda Ospedaliera Universitaria di Padova
    Padova, 35128, Italy
  • Osp. Pediatrico Bambin Gesù
    Roma, 00165, Italy
  • Clinical Research Institute S.C.
    Tlalnepantla, 54055, Mexico
  • Oslo Universitetssykehus HF, Rikshospitalet
    Oslo, N-0372, Norway
  • Independent Public Teaching Children's Hospital
    Warsaw, 02091, Poland
  • CHULC, EPE - Hospital Dona Estefânia
    Lisboa, 1169-045, Portugal
  • Centro Hospitalar Universitário de Lisboa Norte, EPE - Hospital Santa Maria
    Lisboa, 1649-035, Portugal
  • Children's Hematology,Oncology&Immunology na Rogachev,Moscow
    Moscow, 117198, Russian Federation
  • State Novosibirsk Regional Clinical Hospital
    Novosibirsk, 630087, Russian Federation
  • St. Petersburg State Pediatric University
    St. Petersburg, 194100, Russian Federation
  • Hospital Vall d'Hebron
    Barcelona, 08035, Spain
  • Hospital Virgen del Rocío
    Sevilla, 41013, Spain
  • Regional Children Clinical Hospital, Pulmonology, Kharkiv
    Kharkiv, 61093, Ukraine
  • Institute of Phthisiology and Pulmonology n. a. F.G.Yanovsky
    Kyiv, 03680, Ukraine
  • Regional clinical children hospital, Zaporizhya
    Zaporizhya, 69063, Ukraine
  • Birmingham Children's Hospital
    Birmingham, B4 6NH, United Kingdom
  • King's College Hospital
    London, SE5 9RS, United Kingdom
09

References and documents

Publications

  • Deterding R, Griese M, Deutsch G, Warburton D, DeBoer EM, Cunningham S, Clement A, Schwerk N, Flaherty KR, Brown KK, Voss F, Schmid U, Schlenker-Herceg R, Verri D, Dumistracel M, Schiwek M, Stowasser S, Tetzlaff K, Clerisme-Beaty E, Young LR. Study design of a randomised, placebo-controlled trial of nintedanib in children and adolescents with fibrosing interstitial lung disease. ERJ Open Res. 2021 Jun 21;7(2):00805-2020. doi: 10.1183/23120541.00805-2020. eCollection 2021 Apr. PubMed 34164554 ↗

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization). For more details refer to: https://www.mystudywindow.com/msw/datatransparency

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2019 to primary completion in May 2022, 29 months.

Results were first posted in Jan 2023, 8 months after primary completion.

Of 36 phase 3 interventional studies under Lung Diseases, Interstitial, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 61. This study's 29 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2019
First posted
Sep 17, 2019
StartActual
Dec 3, 2019
Primary completionActual
May 24, 2022
CompletionActual
May 24, 2022
Results first posted
Jan 31, 2023
Last update
Jul 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04093024
Responsible party
Sponsor
First posted
Sep 17, 2019
Start date
Dec 3, 2019
Primary completion
May 24, 2022
Completion
May 24, 2022
Results posted
Jan 31, 2023
Last update
Jul 9, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nintedanib

Start the discussion